- Home
- AG vs SLNO Comparison
AG vs SLNO Comparison
Compare AG & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | SLNO |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AG | SLNO |
|---|---|---|
| Price | $15.01 | $51.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.25 | ★ $110.90 |
| AVG Volume (30 Days) | ★ 16.1M | 1.8M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $965,571,000.00 | $98,675,000.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | $18.81 | $155.86 |
| P/E Ratio | $108.04 | ★ N/A |
| Revenue Growth | ★ 83.84 | N/A |
| 52 Week Low | $5.09 | $41.50 |
| 52 Week High | $16.28 | $90.32 |
Technical Indicators
Market Signals| Indicator | AG | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 48.33 |
| Support Level | $14.84 | $47.80 |
| Resistance Level | $16.28 | $53.10 |
| Average True Range (ATR) | 0.83 | 2.47 |
| MACD | 0.36 | 1.09 |
| Stochastic Oscillator | 78.15 | 79.48 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.